Pds Biotechnology Corporation · NASDAQ:PDSB

Pds Biotechnology — Investor Presentation (September 2026)

28 slides from Pds Biotechnology's investor presentation, September 2026

  1. Slide 1: Overview of PDS Biotech Drug Development Programs (Oncology)

    Overview of PDS Biotech Drug Development Programs (Oncology) NASDAQ: PDSB September 2026 1 © 2026 PDS Biotechnology. All Rights Reserved.

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo

  3. Slide 3: Clinically Validated Immunotherapies for Solid Tumors with High Unmet Need

    Clinically Validated Immunotherapies for Solid Tumors with High Unmet Need PDS0301 (Tumor-Targeted IL-12 Immunocytokine) Designed to concentrate IL-12 in the tumor microenvironment while limiting systemic exposure. In an NCI-led Phase 2 trial in MSS/pMMR metastatic colorectal cancer (mCRC) with live

  4. Slide 4: Pipeline of Tumor-Targeted Immunotherapies

    Pipeline of Tumor-Targeted Immunotherapies THERAPY/TREATMENT INDICATION PHASE 1 PHASE 2 PHASE 3 PARTNER Advanced liver-associated cancers: • metastatic colorectal cancer PDS0301 + Chemotherapy • intrahepatic cholangiocarcinoma In Progress • metastatic adrenocortical carcinoma PDS0301 Biochemically r

  5. Slide 5: Overview of PDS0301

    Overview of PDS0301 5 © 2026 PDS Biotechnology. All Rights Reserved.

  6. Slide 6: Proprietary IL-12 Immunocytokine: PDS0301 – Tumor Targeting Immunocytokine

    Proprietary IL-12 Immunocytokine: PDS0301 – Tumor Targeting Immunocytokine • Tumor-targeted cytokine (IL-12) designed to accumulate within the tumor microenvironment (TME) with sustained presence in solid tumors5 • Designed to address limitations of cytokine therapy and targets and accumulates in th

  7. Slide 7: PDS0301: Targets and Modifies the TME of Solid Tumors to become Less Resistant to Treatment

    PDS0301: Targets and Modifies the TME of Solid Tumors to become Less Resistant to Treatment with Added T Cell & NK Cell Activation in the TME5-7 NHS76 THE CHALLENGE The TME is a highly immune suppressive environment that can block T cell Tumor Necrosis Targeting Antibody – and NK activity within sol

  8. Slide 8: Phase 2 Clinical Study of PDS0301 and Chemotherapy in mCRC with Liver Metastases

    Phase 2 Clinical Study of PDS0301 and Chemotherapy in mCRC with Liver Metastases 8 © 2026 PDS Biotechnology. All Rights Reserved.

  9. Slide 9: Non-Randomized Phase 2 Trial of PDS0301 + Chemotherapy in MSS/pMMR CRC with Liver Metastases

    Non-Randomized Phase 2 Trial of PDS0301+ Chemotherapy as 2L or 3L Therapy in Patients with MSS and pMMR Colorectal Cancer with Liver Metastases Trial Evaluated Various Immune Responses as Potential Predictive Biomarkers Study Key Entry Study Endpoints Treatment Criteria Design Therapies were adminis

  10. Slide 10: Chemotherapy + PDS0301 may Promote Durable Responses in Metastatic CRC

    Chemotherapy + PDS0301 may Promote Durable Responses in Metastatic CRC1,2 Encouraging Responses at 6 months Post Treatment; Monitoring of Durability Continues Consistent with the PDS0301 promotion of self-renewing memory T cells HAIP Therapy RECIST Response at 6 Months PDS01ADC + HAIP Therapy Chemot

  11. Slide 11: 24-Month Survival Rate of Approximately 80%

    24-Month Survival Rate of Approximately 80%1,2 PDS0301 + Chemotherapy Appears to Provide Survival Benefit Probability of Survival (%) 100 Chemotherapy (N=20)* Chemotherapy + PDS0301 (N=22)* 50 0 0 20 40 60 80 Survival Post Treatment (Months) 3 *Sequentially performed studies at the same clinical sit

  12. Slide 12: Promising Results with PDS0301 in MSS/pMMR mCRC with Liver Metastases

    Promising Results with PDS0301 in MSS/pMMR Metastatic Colorectal Cancer (mCRC) with Liver Metastases Exelixis11 Incyte12 NCI/PDS Biotech1,2 mCRC w/wo liver Indication mCRC w/wo liver metastases mCRC with liver metastases metastases Zanzalintinib + Chemotherapy Therapy INCA33890 (TGFβR2×PD-1) atezoli

  13. Slide 13: mCRC Program Provides Significant Value Creation Opportunity

    mCRC Program Provides Significant Value Creation Opportunity Current Focus 2L mCRC Types • 294,500 cases of mCRC in the 7 major markets, projected to increase through 2034 71.4 % Objective Response Rate1,2 <30% benchmark)* 80 • In 2024, total market size of mCRC in the 7 24-month survival rate1,2 ma

  14. Slide 14: PDS0301 Value-Creating Milestones Over the Next 6-18 Months

    PDS0301 Value-Creating Milestones Over the Next 6-18 Months Demonstrate Potential Breadth in Solid Tumors Q4 2026/Q1 2027: Q1/Q2 2027: NCI-led - Q2/3 2027: Metastatic Q2 2028: Phase 3 - Q4 2027: Biochemically Biochemically recurrent Colorectal cancer with castration resistant Colorectal cancer with

  15. Slide 15: PDS0301: Tumor-Targeted IL-12 with Clinical Proof of Concept in Solid Tumors

    PDS0301: Tumor-Targeted IL-12 with Clinical Proof of Concept in Solid Tumors Key Takeaways ✓ Targeted delivery to the tumor addresses limitations that have constrained IL-12 therapy. Fusion to the NHS76 antibody anchors PDS0301 in the tumor microenvironment, sustains presence in the tumor, and preve

  16. Slide 16: Overview of PDS0101 in HPV16-Positive HNSCC

    Overview of PDS0101 in HPV16-Positive HNSCC 16 © 2026 PDS Biotechnology. All Rights Reserved.

  17. Slide 17: HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC

    HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC 30,000 Annual Number of Oropharyngeal Cancer Cases HPV16+ HNSCC Rapidly Increasing in US/EU 25,000 • Poor uptake of HPV vaccine15,16 20,000 HPV16+ 15,000 PDS Biotech focus • Changing sexual behavior17 10,000 • Unique pathophysiolo

  18. Slide 18: HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes

    HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes PUBLISHED EVIDENCE NO FDA-APPROVED HPV16 TARGETED THERAPIES Two head-to-head studies demonstrate that HPV16-positive patients have statistically worse survival compared to other patient groups: The rapidly increasing incidence of

  19. Slide 19: Proprietary Cancer Vaccine Platform: The Versamune Platform

    Proprietary Cancer Vaccine Platform: The Versamune® Platform - Mechanism for Targeted Immune Attack on Tumors • Immunotherapy (cancer vaccine) platform R-DOTAP forms Nanoparticles sized 100- designed to generate killer CD8+ T-cell spherical bilayers in 200nm to promote uptake aqueous environment by

  20. Slide 20: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors

    PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors21 LYMPH NODE TUMOR Dendritic Cell HPV16 E6 & E7 Versamune® + HPVmix (PDS0101) MHC class I CD8+ killer T cell Targeted T Cells Track to Tumor Versamune® CD4+ Activated CD8+ MHC class II helper T cell Killer T Cell Subcutaneous Inje

  21. Slide 21: Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors

    Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors VERSATILE-002: PDS0101 + Pembrolizumab in 1L HPV16+ R/M HNSCC Key Entry Study Study Criteria for ICI Endpoints Treatment Design Naïve Subjects PDS0101 HPV16-positive R/M Single-arm study Primary HNSCC tumors Best over

  22. Slide 22: PDS0101 + Pembrolizumab: mOS of 39.3 Months

    PDS0101 + Pembrolizumab: mOS of 39.3 Months3 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy4 Durable Survival: 11 Patients Surpassed 30 Months mOS = Median Overall Survival. No head-to-head studies have been performed. 22

  23. Slide 23: PDS0101 + Pembrolizumab: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients

    PDS0101 + Pembrolizumab: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients3 63% of recruited patients into 100 the study had low CPS 1-193 Best Percentage Change from Baseline Response in Target Lesions (mITT population) Complete Response (CR) 5/53 9.4% 75 Partial Response (PR) 14/53 2

  24. Slide 24: PDS0101 + Pembrolizumab: Well-tolerated with a Low Incidence of Adverse Events

    PDS0101 + Pembrolizumab: Well-tolerated with a Low Incidence of Adverse Events3 Treatment related adverse events (TRAEs) Most common Non-Injection n (%) n (%) by Grade in ICI naïve and resistant patients Site Reaction TRAEs Any Combination TRAE 76 (87.4) Fatigue 30 (34.5) Grade 1 40 (46.0) Headache

  25. Slide 25: PDS0101 + Pembrolizumab: Well-Positioned in 1L HPV16+ R/M HNSCC

    PDS0101 + Pembrolizumab: Well-Positioned in 1L HPV16+ R/M HNSCC PDS0101: Only Subcutaneous Combination Therapy in Late-stage Development for 1L HPV16+ HNSCC Combinations with pembrolizumab Genmab27 Bicara28 BioNTech29 PDS Biotech3 39.3 months Median OS Not disclosed 21.3 months 22.6 months 95% CI (2

  26. Slide 26: Pipeline of Tumor-Targeted Immunotherapies

    Pipeline of Tumor-Targeted Immunotherapies THERAPY/TREATMENT INDICATION PHASE 1 PHASE 2 PHASE 3 PARTNER Advanced liver-associated cancers: • metastatic colorectal cancer PDS0301 + Chemotherapy • intrahepatic cholangiocarcinoma In Progress • metastatic adrenocortical carcinoma PDS0301 Biochemically r

  27. Slide 27: References

    References 1. Eade AV et al, Tumor-Targeted IL-12 (PDS01ADC) With Hepatic Artery Infusion Pump Therapy for Colorectal Liver Metastases: Interim Analysis of a Nonrandomized Phase II Trial; JCO Oncol Adv. 2026 Mar 10;3(1):e2500173. doi: 10.1200/oa-25-00173 2. Eade AV et al, National Cancer Institute,

  28. Slide 28: References

    References 15. Damgacioglu H, Sonawane K, Chhatwal J, et al. Long-term impact of HPV vaccination and COVID-19 pandemic on oropharyngeal cancer incidence and burden among men in the USA: A modeling Study. The Lancet Regional Health – Americas. 2022;8:100143. 16. Tabatabaeian H et al, Navigating thera

PDS Biotechnology — Investor Presentation (September 2026) on 6ix